Investigational drug · Phase 2
and oxaliplatin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3,025
Any phase or sponsor naming "and oxaliplatin"
First trial start
2020
Nov 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "and oxaliplatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "and oxaliplatin" as an intervention, largest first.
- Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records DatabasesActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT07861386 · 9,978 participants · Start Aug 20, 2026 · Primary completion Aug 20, 2027
Drug: FOLFIRI plus bevacizumab; mFOLFOX6 plus bevacizumab · For: Metastatic Colorectal Cancer (mCRC)
Sites: Somerville, Massachusetts
- Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and IIIPivotal-lookingStatus unknown
State Key Laboratory of Cancer BiologyResearch network
NCT01196260 · 8,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2020
Drug: Capecitabine and Oxaliplatin · For: Colorectal Cancer
Sites: Xi'an, China
- Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal CancerPivotal-lookingCompleted
Cancer Research UK, GlasgowAcademic, hospital or other
NCT00749450 · 6,088 participants · Start Mar 2008 · Primary completion Nov 2017
Drug: capecitabine; fluorouracil and 1 more · For: Colorectal Cancer
Sites: Glasgow, United Kingdom
- Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II EvaluationPivotal-lookingStatus unknown
Technische Universität DresdenAcademic, hospital or other
NCT04089631 · 4,812 participants (planned) · Start Jun 26, 2020 · Primary completion Jun 2023
Drug: Capecitabine · For: Colon Cancer Stage II
Sites: Dresden, Germany
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerPivotal-lookingCompleted
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteAcademic, hospital or other
NCT00646607 · 3,756 participants · Start Jun 2007 · Primary completion Apr 2013
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin); FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin) · For: Colon Cancer
Sites: Casale Monferrato, Italy; Ancona, Italy; Fabriano, Italy · 111 sites in all
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00112918 · 3,451 participants · Start Dec 2004 · Primary completion Jun 2010
Drug: Bevacizumab; Capecitabine and 3 more · For: Colorectal Cancer
Sites: Los Angeles, California
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00079274 · 3,397 participants · Start Feb 2004 · Primary completion Nov 2012
Drug: irinotecan hydrochloride; oxaliplatin and 4 more · For: Adenocarcinoma of the Colon; Stage III Colon Cancer
Sites: Anniston, Alabama; Huntsville, Alabama; Mobile, Alabama · 894 sites in all
- Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00975897 · 3,240 participants (planned) · Start Jul 2009 · Primary completion Aug 2010
Drug: bevacizumab; cetuximab and 4 more · For: Colorectal Cancer
Sites: Leeds, United Kingdom; Belfast, United Kingdom; Cardiff, United Kingdom
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00096278 · 2,710 participants · Start Sep 15, 2004 · Primary completion Mar 12, 2009
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 4 more
Sites: Pittsburgh, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- COL11A1-packaged extracellular vesicles from THY1+ cancer-associated fibroblasts confer oxaliplatin resistance and unfavorable prognosis in gastric cancer.
Xiong S, Zhao Z, Zhang Y, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy.
Chao SW, Tsai WC, Chang YH, et al. · Drug Deliv 2026
- Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2ߙ×ߙ2 factorial phase 3 trial.
Reni M, Macchini M, Orsi G, et al. · Lancet 2026
- Safety and efficacy of the FOLFOX regimen in patients with metastatic gastrointestinal cancers and severe hyperbilirubinemia: A real-world experience.
Başkurt K, Uyar GC, Yeşilbaş E, et al. · Oncol Lett 2026
- Tumor-to-tumor metastasis of colorectal adenocarcinoma within a gonadotroph pituitary adenoma.
Murasawa S, Isozaki F, Fukasawa-Maeda M, et al. · JCEM Case Rep 2026
- Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal neoplasms: A Brazilian cancer center experience.
Marques TMDM, Lourenco SR, Kupper BEC, et al. · Surgery 2026
Also in development for HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.